- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.01. | EXTRAWELL PHAR (00858): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 2 | HKEx | ||
| 20.01. | EXTRAWELL PHAR (00858): CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGES IN COMPOSITION OF BOARD COMMITTEES | 1 | HKEx | ||
| 31.12.25 | EXTRAWELL PHAR (00858): CHANGE OF BUILDING NAME OF HEAD OFFICE AND PRINCIPAL PLACE OF BUSINESS IN HONG KONG | 2 | HKEx | ||
| 30.12.25 | EXTRAWELL PHAR (00858): DISCLOSEABLE TRANSACTION AND CONNECTED TRANSACTION AT SUBSIDIARY LEVEL IN RELATION TO A SHARE BUY-BACK TRANSACTION OF A NON-WHOLLY ... | 3 | HKEx | ||
| 30.12.25 | EXTRAWELL PHAR (00858): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| EXTRAWELL PHARMACEUTICAL Aktie jetzt für 0€ handeln | |||||
| 30.12.25 | EXTRAWELL PHAR (00858): CHANGE OF CHIEF EXECUTIVE OFFICER | 3 | HKEx | ||
| 22.12.25 | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF INTERIM REPORT 2025/26 | 2 | HKEx | ||
| 22.12.25 | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF INTERIM REPORT 2025/26 | 2 | HKEx | ||
| 22.12.25 | EXTRAWELL PHAR (00858): INTERIM REPORT 2025/26 | 1 | HKEx | ||
| 19.12.25 | EXTRAWELL PHAR (00858): GRANT OF SHARE OPTIONS | 2 | HKEx | ||
| 02.12.25 | EXTRAWELL PHAR (00858): MAJOR TRANSACTION - PROPOSED FOURTH AMENDMENTS TO THE TERMS AND CONDITIONS OF THE BONDS | - | HKEx | ||
| 28.11.25 | EXTRAWELL PHAR (00858): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2025 | 1 | HKEx | ||
| 20.11.25 | EXTRAWELL PHAR (00858): PROFIT WARNING | 2 | HKEx | ||
| 13.11.25 | EXTRAWELL PHAR (00858): DATE OF BOARD MEETING | 1 | HKEx | ||
| 10.09.25 | EXTRAWELL PHAR (00858): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 10.09.25 | EXTRAWELL PHAR (00858): COMPLETION OF ISSUE OF NEW SHARES UNDER GENERAL MANDATE AND BUSINESS UPDATE | - | HKEx | ||
| 22.08.25 | EXTRAWELL PHAR (00858): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 22 AUGUST 2025 | 2 | HKEx | ||
| 15.08.25 | EXTRAWELL PHAR (00858): ISSUE OF NEW SHARES UNDER GENERAL MANDATE | 1 | HKEx |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IONIS PHARMACEUTICALS | 71,92 | -1,72 % | Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 6 Analysts | ||
| CSPC PHARMA | 1,031 | +0,49 % | HSI Closes at 26,834, Up 59 pts; HSTI Closes at 5,467, Down 59 pts; CSPC PHARMA Up over 8%; NEW ORIENTAL, HSBC HOLDINGS, MTR CORPORATION, POWER ASSETS, CIMC Hit New Highs; Market Turnover Rises | ||
| SELLAS LIFE SCIENCES | 3,150 | -0,32 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) | Contract Research Organization for the REGAL trial has informed the Company that 72 events have occurred in the trial as of December 26, 2025; SELLAS remains blinded to trial outcomesTiming of the... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 19,970 | +0,25 % | Acadia Pharmaceuticals Inc.: Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union | - Company expects to receive a negative opinion following oral explanation feedback and intends to request re-examination upon review of formal adoption.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD)... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 20,550 | -0,63 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update | Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Guidance... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 401,30 | -0,62 % | Madrigal Pharmaceuticals stock maintains Buy rating at B.Riley on strong Rezdiffra growth | ||
| ENZON PHARMACEUTICALS | 0,050 | 0,00 % | Enzon Pharmaceuticals, Inc: Enzon Announces Commencement of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock in Connection With Viskase Merger | CRANFORD, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) ("Enzon" or the "Company"), today announced that it has commenced an exchange offer (the "Offer") involving... ► Artikel lesen | |
| OPUS GENETICS | 2,490 | -1,97 % | Opus Genetics, Inc.: Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa | The trial is funded through Abu Dhabi's Healthcare Research and Innovation FundClinical development activities will commence at Cleveland Clinic Abu Dhabi in 2026MERTK-related retinitis pigmentosa... ► Artikel lesen | |
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information | Northvale, New Jersey--(Newsfile Corp. - November 14, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| SAVARA | 4,440 | +2,78 % | Savara Inc.: Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI* | -- Once Granted, the Patent Will Provide Protection for MOLBREEVI in Europe Until March 2041 -- -- Savara Was Also Recently Granted a European Patent Covering the Investigational Drug-Device... ► Artikel lesen | |
| GALECTIN THERAPEUTICS | 2,240 | -1,75 % | Galectin Therapeutics Inc.: Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March ... | NORCROSS, Ga., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 1,260 | -3,08 % | Biodexa Pharmaceuticals PLC: Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST | February 4, 2026 Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST Novel Mechanism of Action Shown to be Effective in TKI Resistant PDX Models... ► Artikel lesen | |
| NOVABAY PHARMACEUTICALS | 0,725 | +7,41 % | XFRA B9P0: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| NEURIZON THERAPEUTICS | 0,049 | -7,55 % | NEURIZON THERAPEUTICS LIMITED: Change of Director's Interest Notice | ||
| CIPHER PHARMACEUTICALS | 7,950 | -10,17 % | Cipher Pharmaceuticals Inc: Cipher Pharmaceuticals gets Health Canada NDS review |
Das Unternehmen EXTRAWELL PHARMACEUTICAL HOLDINGS LTD kann der Branche Pharma zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EXTRAWELL PHARMACEUTICAL HOLDINGS LTD finden Sie auf Wallstreet Online.